ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 100 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.65 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,129,165 | -33.9% | 1,040,754 | 0.0% | 0.75% | -56.5% |
| Q2 2023 | $10,792,619 | +28.2% | 1,040,754 | 0.0% | 1.73% | +5.0% |
| Q1 2023 | $8,419,700 | -88.3% | 1,040,754 | -77.2% | 1.64% | -86.4% |
| Q4 2022 | $71,882,402 | +0.1% | 4,563,962 | 0.0% | 12.11% | +9.2% |
| Q3 2022 | $71,837,000 | +12.8% | 4,563,962 | 0.0% | 11.08% | -11.7% |
| Q2 2022 | $63,713,000 | -19.0% | 4,563,962 | 0.0% | 12.55% | -1.6% |
| Q1 2022 | $78,683,000 | +18.6% | 4,563,962 | 0.0% | 12.75% | +40.5% |
| Q4 2021 | $66,360,000 | -19.2% | 4,563,962 | 0.0% | 9.07% | -14.0% |
| Q3 2021 | $82,151,000 | +2.5% | 4,563,962 | 0.0% | 10.55% | +8.5% |
| Q2 2021 | $80,143,000 | -14.5% | 4,563,962 | +22.7% | 9.72% | -4.4% |
| Q1 2021 | $93,759,000 | +641.3% | 3,720,582 | +90.3% | 10.17% | +446.9% |
| Q4 2020 | $12,648,000 | – | 1,954,932 | – | 1.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
| COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
| Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
| VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
| Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
| Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
| Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
| Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
| Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |